Cargando…
The Effects of Tocotrienol-Rich Vitamin E (Tocovid) on Diabetic Neuropathy: A Phase II Randomized Controlled Trial
Chronic hyperglycemia increases oxidative stress, activates inflammatory pathways and reduces nerve growth factor (NGF) among diabetic patients, which contribute to development of diabetic peripheral neuropathy (DPN). Tocotrienol-Rich Vitamin E (Tocovid) possesses potent antioxidant and anti-inflamm...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284602/ https://www.ncbi.nlm.nih.gov/pubmed/32456230 http://dx.doi.org/10.3390/nu12051522 |
_version_ | 1783544505601884160 |
---|---|
author | Ng, Yeek Tat Phang, Sonia Chew Wen Tan, Gerald Chen Jie Ng, En Yng Botross Henien, Nevein Philip M. Palanisamy, Uma Devi Ahmad, Badariah Abdul Kadir, Khalid |
author_facet | Ng, Yeek Tat Phang, Sonia Chew Wen Tan, Gerald Chen Jie Ng, En Yng Botross Henien, Nevein Philip M. Palanisamy, Uma Devi Ahmad, Badariah Abdul Kadir, Khalid |
author_sort | Ng, Yeek Tat |
collection | PubMed |
description | Chronic hyperglycemia increases oxidative stress, activates inflammatory pathways and reduces nerve growth factor (NGF) among diabetic patients, which contribute to development of diabetic peripheral neuropathy (DPN). Tocotrienol-Rich Vitamin E (Tocovid) possesses potent antioxidant and anti-inflammatory properties which are postulated to target these pathogeneses in order to ameliorate DPN. This study aims to evaluate the effects of Tocovid on nerve conduction parameters and serum biomarkers among diabetic patients. This multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial was conducted on 80 eligible participants. The intervention group (n = 39) was randomly allocated to receive 200 mg of Tocovid twice a day, and the control group (n = 41) received placebo twice a day. At the end of eight weeks, the nerve conduction parameters, as assessed by nerve conduction study, as well as serum biomarkers (NGF, malondialdehyde, vascular cell adhesion molecule 1, tumor necrosis factor receptor 1 and thromboxane B2) were compared between the two groups. Compared to placebo, Tocovid significantly improves the nerve conduction velocities of all nerves (+1.25 m/s, interquartile range [IQR] 3.35, p < 0.001, median nerve; +1.60 m/s, IQR 1.80, p < 0.001, sural nerve; +0.75 m/s, IQR 2.25, p < 0.001, tibial nerve). Meanwhile, the levels of serum NGF were significantly higher in the Tocovid group as compared to placebo at eight weeks post-intervention. Participants receiving Tocovid illustrated highly significant improvement in terms of nerve conduction velocities for all nerves tested after eight weeks of supplementation. In addition, Tocovid supplementation elevated the levels of serum NGF, in which its increase is postulated to reflect enhanced neuronal functions. This novel finding suggests that Tocovid could be a disease-modifying agent targeting serum NGF to improve nerve conduction velocities. |
format | Online Article Text |
id | pubmed-7284602 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72846022020-06-19 The Effects of Tocotrienol-Rich Vitamin E (Tocovid) on Diabetic Neuropathy: A Phase II Randomized Controlled Trial Ng, Yeek Tat Phang, Sonia Chew Wen Tan, Gerald Chen Jie Ng, En Yng Botross Henien, Nevein Philip M. Palanisamy, Uma Devi Ahmad, Badariah Abdul Kadir, Khalid Nutrients Article Chronic hyperglycemia increases oxidative stress, activates inflammatory pathways and reduces nerve growth factor (NGF) among diabetic patients, which contribute to development of diabetic peripheral neuropathy (DPN). Tocotrienol-Rich Vitamin E (Tocovid) possesses potent antioxidant and anti-inflammatory properties which are postulated to target these pathogeneses in order to ameliorate DPN. This study aims to evaluate the effects of Tocovid on nerve conduction parameters and serum biomarkers among diabetic patients. This multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial was conducted on 80 eligible participants. The intervention group (n = 39) was randomly allocated to receive 200 mg of Tocovid twice a day, and the control group (n = 41) received placebo twice a day. At the end of eight weeks, the nerve conduction parameters, as assessed by nerve conduction study, as well as serum biomarkers (NGF, malondialdehyde, vascular cell adhesion molecule 1, tumor necrosis factor receptor 1 and thromboxane B2) were compared between the two groups. Compared to placebo, Tocovid significantly improves the nerve conduction velocities of all nerves (+1.25 m/s, interquartile range [IQR] 3.35, p < 0.001, median nerve; +1.60 m/s, IQR 1.80, p < 0.001, sural nerve; +0.75 m/s, IQR 2.25, p < 0.001, tibial nerve). Meanwhile, the levels of serum NGF were significantly higher in the Tocovid group as compared to placebo at eight weeks post-intervention. Participants receiving Tocovid illustrated highly significant improvement in terms of nerve conduction velocities for all nerves tested after eight weeks of supplementation. In addition, Tocovid supplementation elevated the levels of serum NGF, in which its increase is postulated to reflect enhanced neuronal functions. This novel finding suggests that Tocovid could be a disease-modifying agent targeting serum NGF to improve nerve conduction velocities. MDPI 2020-05-23 /pmc/articles/PMC7284602/ /pubmed/32456230 http://dx.doi.org/10.3390/nu12051522 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ng, Yeek Tat Phang, Sonia Chew Wen Tan, Gerald Chen Jie Ng, En Yng Botross Henien, Nevein Philip M. Palanisamy, Uma Devi Ahmad, Badariah Abdul Kadir, Khalid The Effects of Tocotrienol-Rich Vitamin E (Tocovid) on Diabetic Neuropathy: A Phase II Randomized Controlled Trial |
title | The Effects of Tocotrienol-Rich Vitamin E (Tocovid) on Diabetic Neuropathy: A Phase II Randomized Controlled Trial |
title_full | The Effects of Tocotrienol-Rich Vitamin E (Tocovid) on Diabetic Neuropathy: A Phase II Randomized Controlled Trial |
title_fullStr | The Effects of Tocotrienol-Rich Vitamin E (Tocovid) on Diabetic Neuropathy: A Phase II Randomized Controlled Trial |
title_full_unstemmed | The Effects of Tocotrienol-Rich Vitamin E (Tocovid) on Diabetic Neuropathy: A Phase II Randomized Controlled Trial |
title_short | The Effects of Tocotrienol-Rich Vitamin E (Tocovid) on Diabetic Neuropathy: A Phase II Randomized Controlled Trial |
title_sort | effects of tocotrienol-rich vitamin e (tocovid) on diabetic neuropathy: a phase ii randomized controlled trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284602/ https://www.ncbi.nlm.nih.gov/pubmed/32456230 http://dx.doi.org/10.3390/nu12051522 |
work_keys_str_mv | AT ngyeektat theeffectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial AT phangsoniachewwen theeffectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial AT tangeraldchenjie theeffectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial AT ngenyng theeffectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial AT botrosshenienneveinphilip theeffectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial AT mpalanisamyumadevi theeffectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial AT ahmadbadariah theeffectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial AT abdulkadirkhalid theeffectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial AT ngyeektat effectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial AT phangsoniachewwen effectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial AT tangeraldchenjie effectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial AT ngenyng effectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial AT botrosshenienneveinphilip effectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial AT mpalanisamyumadevi effectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial AT ahmadbadariah effectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial AT abdulkadirkhalid effectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial |